208 related articles for article (PubMed ID: 27521731)
21. Prolactin-Secreting Lung Adenocarcinoma Metastatic to the Pituitary Mimicking a Prolactinoma: A Case Report.
Yao H; Rui W; Zhang Y; Liu Y; Lin S; Tang H; Zhao W; Wu Z
Neurosurgery; 2019 Oct; 85(4):E773-E778. PubMed ID: 30137505
[TBL] [Abstract][Full Text] [Related]
22. Cabergoline treatment in a case of macroprolactinoma after delivery.
Falsetti L
Acta Eur Fertil; 1995; 26(3):105-7. PubMed ID: 9098469
[TBL] [Abstract][Full Text] [Related]
23. [Cabergoline-induced tension pneumocephalus in a patient with giant invasive prolactinoma. Case report].
Castro-Castro J; Torre-Eiriz JA; Pinzón-Millán A; Pastor-Zapata A
Neurocirugia (Astur); 2011 Dec; 22(6):558-61; discussion 561. PubMed ID: 22167286
[TBL] [Abstract][Full Text] [Related]
24. Pituitary apoplexy associated with cabergoline therapy.
Chng E; Dalan R
J Clin Neurosci; 2013 Dec; 20(12):1637-43. PubMed ID: 24113159
[TBL] [Abstract][Full Text] [Related]
25. Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients.
Vroonen L; Jaffrain-Rea ML; Petrossians P; Tamagno G; Chanson P; Vilar L; Borson-Chazot F; Naves LA; Brue T; Gatta B; Delemer B; Ciccarelli E; Beck-Peccoz P; Caron P; Daly AF; Beckers A
Eur J Endocrinol; 2012 Nov; 167(5):651-62. PubMed ID: 22918301
[TBL] [Abstract][Full Text] [Related]
26. Granulomatosis with polyangiitis masquerading as pituitary adenoma with apoplexy.
Piper K; Beldick SR; Karsy M; Allawh T; Shirodkar M; Miller J; Kiriakidou M; Curtis M; Evans JJ
Mod Rheumatol Case Rep; 2021 Jul; 5(2):342-346. PubMed ID: 33784948
[TBL] [Abstract][Full Text] [Related]
27. Temozolomide retreatment in a recurrent prolactin-secreting pituitary adenoma: Hormonal and radiographic response.
Strowd RE; Salvatori R; Laterra JJ
J Oncol Pharm Pract; 2016 Jun; 22(3):517-22. PubMed ID: 25616657
[TBL] [Abstract][Full Text] [Related]
28. Cystic degeneration of macroprolactinoma on long-term cabergoline.
Sharif DA; Nkonge FM; Chawda S; Benjamin J; Stojanović ND
J Clin Endocrinol Metab; 2010 Aug; 95(8):3593-4. PubMed ID: 20685886
[No Abstract] [Full Text] [Related]
29. Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men.
Shimon I; Benbassat C; Hadani M
Eur J Endocrinol; 2007 Feb; 156(2):225-31. PubMed ID: 17287412
[TBL] [Abstract][Full Text] [Related]
30. How to investigate and treat: headache and hyperprolactinemia.
Bussone G; Usai S; Moschiano F
Curr Pain Headache Rep; 2012 Aug; 16(4):365-70. PubMed ID: 22639180
[TBL] [Abstract][Full Text] [Related]
31. Pituitary dysfunction in granulomatosis with polyangiitis.
Vega-Beyhart A; Medina-Rangel IR; Hinojosa-Azaola A; Fernández-Barrio M; Vargas-Castro AS; García-Inciarte L; Guzmán-Pérez A; Torres-Victoria TR; Martínez-Sánchez FD; Pérez-Guzmán MC; Hinojosa-Amaya JM; León-Suárez A; Gómez-Sámano MA; Gómez-Pérez FJ; Cuevas-Ramos D
Clin Rheumatol; 2020 Feb; 39(2):595-606. PubMed ID: 31446541
[TBL] [Abstract][Full Text] [Related]
32. The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type.
Bolko P; Jaskuła M; Waśko R; Wołuń M; Sowiński J
Pol Arch Med Wewn; 2003 May; 109(5):489-95. PubMed ID: 14768178
[TBL] [Abstract][Full Text] [Related]
33. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.
Colao A; Di Sarno A; Cappabianca P; Di Somma C; Pivonello R; Lombardi G
N Engl J Med; 2003 Nov; 349(21):2023-33. PubMed ID: 14627787
[TBL] [Abstract][Full Text] [Related]
34. Prolactinoma - which patients react favorably to cabergoline medication?
Karatas S; Hacioglu Y; Rakicioglu T
Endocr Regul; 2022 Oct; 56(4):279-283. PubMed ID: 36270341
[No Abstract] [Full Text] [Related]
35. Evaluaton of therapy with cabergoline in men with macroprolactinoa.
Andrysiak-Mamos E; Kaźmierczyk-Puchalska A; Zochowska E; Sowińska-Przepiera E; Sagan L; Kojder I; Syrenicz A
Pomeranian J Life Sci; 2015; 61(3):263-9. PubMed ID: 27344867
[TBL] [Abstract][Full Text] [Related]
36. Cabergoline: long-acting oral treatment of hyperprolactinemic disorders.
Ferrari C; Mattei A; Melis GB; Paracchi A; Muratori M; Faglia G; Sghedoni D; Crosignani PG
J Clin Endocrinol Metab; 1989 Jun; 68(6):1201-6. PubMed ID: 2656736
[TBL] [Abstract][Full Text] [Related]
37. The first report of cabergoline-induced immune hemolytic anemia in an adolescent with prolactinoma.
Gürbüz F; Yağcı-Küpeli B; Kör Y; Yüksel B; Zorludemir S; Gürbüz BB; Küpeli S
J Pediatr Endocrinol Metab; 2014 Jan; 27(1-2):159-63. PubMed ID: 23945126
[TBL] [Abstract][Full Text] [Related]
38. Pons herniation into skull base after cabergoline therapy of giant prolactinoma.
Moles Herbera J; Rivero Celada D; Montejo Gañan I; Fustero de Miguel D; Fuentes Uliaque C; Vela Marín AC
Pituitary; 2015 Feb; 18(1):68-71. PubMed ID: 24522845
[TBL] [Abstract][Full Text] [Related]
39. Serial 3 T magnetic resonance imaging during cabergoline treatment of macroprolactinomas.
Kurosaki M; Kambe A; Watanabe T; Fujii S; Ogawa T
Neurol Res; 2015 Apr; 37(4):341-6. PubMed ID: 25376133
[TBL] [Abstract][Full Text] [Related]
40. Unusual late development of dopamine agonist resistance in two women with hyperprolactinaemia associated with transition from micro to macroadenoma.
McCall D; Hunter SJ; Cooke RS; Herron B; Sheridan B; Atkinson AB
Clin Endocrinol (Oxf); 2007 Jan; 66(1):149-50. PubMed ID: 17201816
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
